Cytokines from the tumor microenvironment modulate sirtinol cytotoxicity in A549 lung carcinoma cells

Cytokine

Volumn 64, Issue 1, 2013, Pages 196-207

  Pal, Shyama ^a   Shankar, Bhavani S ^a   Sainis, Krishna B ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

IGF 1; Necroptosis; SIRT1; TRAIL; Tumor microenvironment

Indexed keywords

AG 658; CISPLATIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SHORT HAIRPIN RNA; SIRTINOL; SIRTUIN 1; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ARTICLE; CARCINOMA CELL; CELL SURVIVAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; NECROPTOSIS; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; TUMOR MICROENVIRONMENT;

IGF-1; INDUCIBLE NITRIC OXIDE SYNTHASE; INOS; INSULIN-LIKE GROWTH FACTOR-1; NECROPTOSIS; SIRT1; SIRTUIN1; TGF-Β; TNF RELATED APOPTOSIS INDUCING LIGAND; TNF-Α; TRAIL; TRANSFORMING GROWTH FACTOR Β; TUMOR MICROENVIRONMENT; TUMOR NECROSIS FACTOR Α;

APOPTOSIS; BENZAMIDES; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; CYTOKINES; DRUG RESISTANCE, NEOPLASM; HUMANS; INSULIN-LIKE GROWTH FACTOR I; JANUS KINASES; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; NAPHTHOLS; PACLITAXEL; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; SIRTUIN 1; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFORMING GROWTH FACTOR BETA; TUMOR MICROENVIRONMENT; TUMOR NECROSIS FACTOR-ALPHA; TYRPHOSTINS;

EID: 84883556221     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.07.029     Document Type: Article

References (48)

1. Giaccone G. Targeted therapy in non-small cell lung cancer. Lung cancer 2002, 38(Suppl 2):S29-S32.
2. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small cell lung cancer collaborative group. BMJ. 1995;311:899-909.
3. Albain K.S., Rusch V.W., Crowley J.J., Rice T.W., Turrisi A.T., Weick J.K., et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995, 13:1880-1892.
4. Raynaud C.M., Mercier O., Commo F., Dartevelle P., Gomez-Roca C., de Montpreville V., et al. Telomere length, telomeric proteins and DNA damage repair proteins are differentially expressed between primary lung tumors and their adrenal metastases. Lung Cancer 2009, 65:144-149.
5. O'Mahony D., Kummar S., Gutierrez M.E. Non-small-cell lung cancer vaccine therapy: a concise review. J Clin Oncol 2005, 23:9022-9028.
6. Baleeiro R.B., Anselmo L.B., Soares F.A., Pinto C.A., Ramos O., Gross J.L., et al. High frequency of immature dendritic cells and altered in situ production of interleukin-4 and tumor necrosis factor-alpha in lung cancer. Cancer Immunol Immunother 2008, 57:1335-1345.
7. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
8. Webb C.P., Vande Woude G.F. Genes that regulate metastasis and angiogenesis. J Neurooncol 2000, 50:71-87.
9. Bissell M.J., Radisky D. Putting tumours in context. Nat Rev Cancer 2001, 1:46-54.
10. Creighton C.J., Bromberg-White J.L., Misek D.E., Monsma D.J., Brichory F., Kuick R., et al. Analysis of tumor-host interactions by gene expression profiling of lung adenocarcinoma xenografts identifies genes involved in tumor formation. Mol Cancer Res 2005, 3:119-129.
11. Cancer Mantovani A. Inflaming metastasis. Nature 2009, 457:36-37.
12. Kopfstein L., Christofori G. Metastasis: cell-autonomous mechanisms versus contributions by the tumor microenvironment. Cell Mol Life Sci 2006, 63:449-468.
13. Kim S., Takahashi H., Lin W.W., Descargues P., Grivennikov S., Kim Y., et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009, 457:102-106.
14. Sauter K.A., Wood L.J., Wong J., Iordanov M., Magun B.E. Doxorubicin and daunorubicin induce processing and release of interleukin-1β through activation of the NLRP3 inflammasome. Cancer Biol Ther 2011, 11:1008-1016.
15. Chen Y.X., Wang Y., Fu C.C., Diao F., Song L.N., Li Z.B., et al. Dexamethasone enhances cell resistance to chemotherapy by increasing adhesion to extracellular matrix in human ovarian cancer cells. Endocr Relat Cancer 2010, 17:39-50.
16. Singh R.K., Lokeshwar B.L. Depletion of intrinsic expression of Interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemotherapeutic drugs. Mol Cancer 2009, 8:57.
17. Roca H., Varsos Z., Pienta K.J. CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation. J Biol Chem 2008, 283:25057-25073.
18. Chowdhury S., Howell G.M., Teggart C.A., Chowdhury A., Person J.J., Bowers D.M., et al. The histone deacetylase inhibitor belinostat represses survivin expression through reactivation of TGF{beta} receptor II leading to cancer cell death. J Biol Chem 2011.
19. Lin W.H., Martin J.L., Marsh D.J., Jack M.M., Baxter R.C. Involvement of insulin-like growth factor binding protein-3 in the effects of the histone deacetylase inhibitor MS-275 in hepatoma cells. J Biol Chem 2011.
20. Zhou C., Qiu L., Sun Y., Healey S., Wanebo H., Kouttab N., et al. Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells. Int J Oncol 2006, 29:269-278.
21. Rhodes D.R., Kalyana-Sundaram S., Mahavisno V., Varambally R., Yu J., Briggs B.B., et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 2007, 9:166-180.
22. Kim Y.M., Talanian R.V., Billiar T.R. Nitric oxide inhibits apoptosis by preventing increases in caspase-3-like activity via two distinct mechanisms. J Biol Chem 1997, 272:31138-31148.
23. Bostedt K.T., Schmid C., Ghirlanda-Keller C., Olie R., Winterhalter K.H., Zapf J. Insulin-like growth factor (IGF) I down-regulates type 1 IGF receptor (IGF 1R) and reduces the IGF I response in A549 non-small-cell lung cancer and Saos-2/B-10 osteoblastic osteosarcoma cells. Exp Cell Res 2001, 271:368-377.
24. Lawlor M.A., Rotwein P. Insulin-like growth factor-mediated muscle cell survival: central roles for Akt and cyclin-dependent kinase inhibitor p21. Mol Cell Biol 2000, 20:8983-8995.
25. Shi Z., Yang W.M., Chen L.P., Yang D.H., Zhou Q., Zhu J., et al. Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of IL-6 and IL-8 production. Breast Cancer Res Treat 2012, 135:737-747.
26. Duan Z., Lamendola D.E., Penson R.T., Kronish K.M., Seiden M.V. Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells. Cytokine 2002, 17:234-242.
27. Pu Y.S., Hour T.C., Chuang S.E., Cheng A.L., Lai M.K., Kuo M.L. Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells. Prostate 2004, 60:120-129.
28. Ara T., Nakata R., Sheard M.A., Shimada H., Buettner R., Groshen S.G., et al. Critical Role of STAT3 in IL-6-Mediated Drug Resistance in Human Neuroblastoma. Cancer Res 2013, 73:3852-3864.
29. Stassi G., Todaro M., Zerilli M., Ricci-Vitiani L., Di Liberto D., Patti M., et al. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res 2003, 63:6784-6790.
30. Kirk P.S., Koreckij T., Nguyen H.M., Brown L.G., Snyder L.A., Vessella R.L., et al. Inhibition of CCL2 signaling in combination with docetaxel treatment has profound inhibitory effects on prostate cancer growth in bone. Int J Mol Sci 2013, 14:10483-10496.
31. Stein U., Walther W., Shoemaker R.H. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells. J Natl Cancer Inst 1996, 88:1383-1392.
32. Lacour S., Micheau O., Hammann A., Drouineaud V., Tschopp J., Solary E., et al. Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells. Oncogene 2003, 22:1807-1816.
33. Mühlethaler-Mottet A., Bourloud K.B., Auderset K., Joseph J.M., Gross N. Drug-mediated sensitization to TRAIL-induced apoptosis in caspase-8-complemented neuroblastoma cells proceeds via activation of intrinsic and extrinsic pathways and caspase-dependent cleavage of XIAP, Bcl-xL and RIP. Oncogene 2004, 23:5415-5425.
34. Evdokiou A., Bouralexis S., Atkins G.J., Chai F., Hay S., Clayer M., et al. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. Int J Cancer 2002, 99:491-504.
35. Garassino M.C., Borgonovo K., Rossi A., Mancuso A., Martelli O., Tinazzi A., et al. Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. Anticancer Res 2009, 29:2691-2701.
36. Koudelakova V., Kneblova M., Trojanec R., Drabek J., Hajduch M. Non-small cell lung cancer - genetic predictors. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2013, 157:125-136.
37. Molina-Arcas M., Hancock D.C., Sheridan C., Kumar M.S., Downward J. Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. Cancer Discovery 2013, 3:548-563.
38. Chen R., Sweet-Cordero E.A. Two is better than one: combining IGF1R and MEK blockade as a promising novel treatment strategy against KRAS-mutant lung cancer. Cancer Discovery 2013, 3:491-493.
39. Yang M.H., Laurent G., Bause A.S., Spang R., German N., Haigis M.C., et al. HDAC6 and SIRT2 regulate the acetylation state and oncogenic activity of mutant K-RAS. Mol Cancer Res 2013.
40. Nakamura H., Takamori S., Fujii T., Ono M., Yamana H., Kuwano M., et al. Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer. Cancer Lett 2005, 230:33-46.
41. Fandy T.E., Shankar S., Ross D.D., Sausville E., Srivastava R.K. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 2005, 7:646-657.
42. Shankar S., Singh T.R., Fandy T.E., Luetrakul T., Ross D.D., Srivastava R.K. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways. Int J Mol Med 2005, 16:1125-1138.
43. Vandenabeele P., Galluzzi L., Vanden Berghe T., Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 2010, 11:700-714.
44. Koutsilieris M., Dimopoulos T., Milathianakis C., Bogdanos J., Karamanolakis D., Pissimissis N., et al. Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis. BJU Int 2007, 100(Suppl 2):60-62.
45. Girnita L., Girnita A., Larsson O. Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor. Proc Natl Acad Sci USA 2003, 100:8247-8252.
46. Gebken J., Feydt A., Brinckmann J., Notbohm H., Müller P.K., Bätge B. Ligand-induced downregulation of receptors for TGF-beta in human osteoblast-like cells from adult donors. J Endocrinol 1999, 161:503-510.
47. Martini L., Waldhoer M., Pusch M., Kharazia V., Fong J., Lee J.H., et al. Ligand-induced down-regulation of the cannabinoid 1 receptor is mediated by the G-protein-coupled receptor-associated sorting protein GASP1. FASEB J 2007, 21:802-811.
48. Li Y., Dowbenko D., Lasky L.A. AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival. J Biol Chem 2002, 277:11352-11361.